Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Regeneron Pharmaceuticals

$1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 12.55% on an annualized basis producing an average annual return of 19.7%. Currently, Regeneron Pharmaceuticals has a market capitalization of $72.59 billion.

Benzinga

Why The First Quarter Could Be A 'High-Water Mark' For Regeneron

The first quarter could represent a "high-water mark" for Regeneron Pharmaceuticals, an analyst said Wednesday.

Investors Business Daily

Regeneron Pharmaceuticals: Q1 Earnings Insights

Regeneron Pharmaceuticals (NASDAQ:REGN) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Earnings Preview: Regeneron Pharmaceuticals

Regeneron Pharmaceuticals (NASDAQ:REGN) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Regeneron Pharmaceuticals will report an earnings per share (EPS) of $10.04.

Benzinga

Where Regeneron Pharmaceuticals Stands With Analysts

Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) within the last quarter:

Benzinga

Here's Why This Analyst Cut Price Target On Regeneron

RBC Capital Markets has lowered Regeneron Pharmaceuticals Inc's price target (NASDAQ:REGN) from $679 to $647 and maintained a Sector Perform rating. Checks suggest that Dupixent (dupilumab) growth/durability should remain strong in new and existing indications, maintaining positive sentiment. The analysts also believe that the concerns about near-term Eylea competition may be overblown. However, high-dose…

Benzinga

If You Invested $100 In Regeneron Pharmaceuticals 10 Years Ago, Here's How Much You Would Have Today

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 10 years by 6.58% on an annualized basis producing an average annual return of 18.92%. Currently, Regeneron Pharmaceuticals has a market capitalization of $78.02 billion.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Analyst Ratings for Regeneron Pharmaceuticals

Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings within the last quarter:

Benzinga

This Is What Whales Are Betting On Regeneron Pharmaceuticals

A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 11 strange trades.

Benzinga

Dow Jones Drops After Market Sell-Off; HP Soars On Warren Buffett Stake

The Dow Jones Industrial Average fell Thursday following two straight days of sharp market sell-offs. HP soared 15% on a Warren Buffett stake.

Investors Business Daily

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 11.29% on an annualized basis producing an average annual return of 18.54%. Currently, Regeneron Pharmaceuticals has a market capitalization of $77.02 billion.

Benzinga

Dow Jones Slides After Stock Market Sell-Off As 10-Year Treasury Yield Surges

The Dow Jones Industrial Average slid Wednesday, extending losses from Tuesday's stock market sell-off, as the 10-year Treasury yield surged.

Investors Business Daily

Dow Jones Falls After Stock Market Rally; Elon Musk To Join Twitter Board

The Dow Jones Industrial Average dropped Tuesday. Tesla CEO Elon Musk is set to join Twitter's board of directors.

Investors Business Daily

Dow Jones Futures: Apple Retakes Entry, Tesla Eyes Buy Point And Twitter Soars On Musk Stake

Dow Jones futures were lower ahead of this week's Fed minutes. Apple and Tesla stock made bullish moves, while Twitter soared 27%.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Executives Sell More Than $262M Of 5 Stocks

Although gold futures traded higher on Monday, there were a few notable insider trades.

Investors Business Daily

Dow Jones Falls; Tesla Rises Despite 'Exceptionally Difficult Quarter'; Twitter Soars On Musk Stake

The Dow Jones Industrial Average fell Monday, as Tesla climbed after the company reported record vehicle deliveries.

Investors Business Daily

Dow Jones Rallies After March Jobs Report Miss; Treasury Yields Surge

The Dow Jones Industrial Average rallied Friday after the March jobs report miss. The 10-year Treasury yield surged.

Investors Business Daily

Dow Jones Falls; Oil Prices Dive As U.S. Eyes Reserve Release

The Dow Jones Industrial Average fell Thursday. Oil prices dived on news that the Biden administration is planning to tap U.S. oil reserves.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Overview Of Value Stocks In The Healthcare Sector

What are Value Stocks?

Investors Business Daily

IBD 50 Stocks To Watch: This Pharma Stock Is Building A New Base

Regeneron Pharmaceuticals rejoins the IBD 50 hot stocks to watch as it builds a new base and could break out.

Benzinga

Recap: Regeneron Pharmaceuticals Q4 Earnings

Regeneron Pharmaceuticals (NASDAQ:REGN) reported its Q4 earnings results on Friday, February 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Benzinga

Earnings Preview For Regeneron Pharmaceuticals

Regeneron Pharmaceuticals (NASDAQ:REGN) is set to give its latest quarterly earnings report on Friday, 2022-02-04. Here's what investors need to know before the announcement. Analysts estimate that Regeneron Pharmaceuticals will likely report an Earnings Per Share (EPS) of $18.11.

Benzinga

Analyst Ratings For Regeneron Pharmaceuticals

Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) within the last quarter:

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.